Sunny Pharmtech Inc. and Vitruvias Therapeutics LLC announced that they have signed two additional agreements to co-develop and market two additional high-value generic drugs. This will expand the original partnership agreement signed on April 2015, from four to five products, and adds a separate agreement which allows Vitruvias to buy in to a late stage, injectable project for $1.75 mil in upfront and milestone payments. The addition of these two projects will strengthen the portfolios of both organizations by adding products in markets that currently exceed $600 mil dollars.

Both projects are in the final stages of development with the first ANDA tentatively scheduled for filing in the second quarter of 2017.